Safety outcomes according to eGFR category in patients treated with alteplase
| eGFR (mL/min/1.73 m2) | Event rate (%) | Crude OR (95% CI) | P value | Adjusted OR (95% CI)* | P value | |
| Symptomatic intracranial haemorrhage within 36 hours | ≥90 | 5 (1.0) | 1 | 1 | ||
| 60–89 | 5 (2.9) | 2.9 (0.83 to 10.14) | 0.10 | 3.38 (0.87 to 13.17) | 0.08 | |
| <60 | 3 (6.0) | 6.14 (1.42 to 26.5) | 0.02 | 10.01 (1.61 to 62.15) | 0.01 | |
| Symptomatic intracranial haemorrhage within 90 days | ≥90 | 6 (1.2) | 1 | 1 | ||
| 60–89 | 6 (3.5) | 2.91 (0.93 to 9.15) | 0.06 | 3.2 (0.92 to 11.11) | 0.07 | |
| <60 | 3 (6.0) | 5.11 (1.24 to 21.08) | 0.02 | 7.84 (1.4 to 43.77) | 0.02 | |
| Parenchymal haematoma 2 intracranial haemorrhage within 90 days | ≥90 | 3 (0.6) | 1 | 1 | ||
| 60–89 | 0 (0.0) | NA | 0.95 | NA | 0.94 | |
| <60 | 0 (0.0) | NA | 0.97 | NA | 0.96 | |
| Any intracranial haemorrhage within 90 days | ≥90 | 26 (5.4) | 1 | 1 | ||
| 60–89 | 17 (9.9) | 1.95 (1.03 to 3.7) | 0.04 | 1.5 (0.74 to 3.04) | 0.26 | |
| <60 | 7 (14.0) | 2.88 (1.18 to 7.02) | 0.02 | 2.08 (0.72 to 6.01) | 0.18 | |
| Other significant haemorrhage events within 90 days | ≥90 | 3 (0.6) | 1 | 1 | ||
| 60–89 | 0 (0.0) | NA | 0.97 | NA | 0.95 | |
| <60 | 2 (4.0) | 6.71 (1.09 to 41.14) | 0.04 | 10.96 (0.8 to 149.76) | 0.07 | |
| Death within 90 days | ≥90 | 14 (2.9) | 1 | 1 | ||
| 60–89 | 10 (5.8) | 1.87 (0. to 4.41) | 0.15 | 0.93 (0.35 to 2.45) | 0.88 | |
| <60 | 11 (22.0) | 9.51 (4.05 to 22.35) | <0.001 | 4.54 (1.48 to 13.91) | 0.008 | |
| Adverse events within 90 days | ≥90 | 408 (84.3) | 1 | 1 | ||
| 60–89 | 157 (91.3) | 1.93 (1.08 to 3.46) | 0.02 | 1.71 (0.93 to 3.15) | 0.08 | |
| <60 | 48 (96.0) | 4.45 (1.06 to 18.69) | 0.04 | 4.07 (0.93 to 17.73) | 0.06 | |
| SeriousAdverse events within 90 days | ≥90 | 55 (11.4) | 1 | 1 | ||
| 60–89 | 38 (22.1) | 2.16 (1.37 to 3.43) | 0.001 | 1.81 (1.1 to 2.98) | 0.02 | |
| <60 | 14 (28.0) | 3.05 (1.55 to 6.00) | 0.001 | 2.36 (1.09 to 5.10) | 0.03 |
Data are expressed as n/N (%), effect size (95% CI) or p value. Risk ratios of the safety outcomes were calculated with their 95% CIs using binary logistic regression.
*The models were adjusted for age, sex, baseline National Institutes of Health Stroke Scale, history of hypertension, history of antiplatelet and anticoagulant drug use, onset-to-needle time and bridging thrombectomy.
eGFR, estimated glomerular filtration rate.